5:38 PM
 | 
Jun 17, 2013
 |  BC Extra  |  Company News

MedImmune, NGM in metabolic deal

MedImmune LLC partnered with NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) to develop and commercialize peptide and antibody therapeutics to treat Type II diabetes and...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >